Merck & Co.’s Keytruda saw its fortunes rise significantly Friday, and not just because its Bristol-Myers Squibb rival failed a key lung cancer study. Keytruda picked up a spanking-new FDA approval, too.
Source: Merck’s Keytruda wins a double-header with new FDA approval in head-and-neck cancer
